These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34293802)

  • 1. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
    Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland.
    Störmann S; Schopohl J; Bullmann C; Terkamp C; Christ-Crain M; Finke R; Flitsch J; Kreitschmann-Andermahr I; Luger A; Stalla G; Houchard A; Helbig D; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):224-233. PubMed ID: 33285601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of lanreotide for neuroendocrine tumor.
    Godara A; Siddiqui NS; Byrne MM; Saif MW
    Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
    Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
    Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
    J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.
    Bianchi A; De Marinis L; Fusco A; Lugli F; Tartaglione L; Milardi D; Mormando M; Lassandro AP; Paragliola R; Rota CA; Della Casa S; Corsello SM; Brizi MG; Pontecorvi A
    J Endocrinol Invest; 2011 Oct; 34(9):692-7. PubMed ID: 22067307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
    Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
    Pavel M; Ćwikła JB; Lombard-Bohas C; Borbath I; Shah T; Pape UF; Capdevila J; Panzuto F; Truong Thanh XM; Houchard A; Ruszniewski P
    Eur J Cancer; 2021 Nov; 157():403-414. PubMed ID: 34597974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
    Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
    Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
    Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
    Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.